GMP Inspection Preparation Checklist: A Tool for Internal Auditing

This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.

Biological-risk-eval-and-mngmnt-for-md-130x160

Biological Risk Evaluation and Management for Medical Devices

Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

Editor's Picks

View all

Stakeholders Urge Congress to Update Clinical Laboratory Diagnostics Legislation

The letter to lawmakers cites an urgent need to reform regulations covering laboratory developed tests and in vitro diagnostics.

Seniors Paying More for Generics Through Medicare Part D, Study Finds

The higher cost sharing did not correspond with an increase in the underlying price of generic drugs, Avalere said.

Home » NEXMED ANNOUNCES TERMINATION OF ALPROX-TD AGREEMENT WITH SCHERING AG AND PROVIDES OPERATIONAL UPDATE

FDAnews Drug Daily Bulletin

NEXMED ANNOUNCES TERMINATION OF ALPROX-TD AGREEMENT WITH SCHERING AG AND PROVIDES OPERATIONAL UPDATE

June 27, 2006

NexMed, Inc., a developer of innovative pharmaceutical products based on its proprietary, NexACT transdermal drug delivery technology, announced today that Schering AG has terminated its license, supply and distribution agreement for Alprox-TD, NexMed's topical treatment for erectile dysfunction (ED), currently in clinical development. It is NexMed's belief that Alprox-TD is no longer a strategic fit for Schering.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=138954)

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 – Fax (703) 538-7676 – Toll free (888) 838-5578.

Recommended Products

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Biological Risk Evaluation and Management for Medical Devices

Events

Cutting the Costs of Clinical Trial Subject Recruitment: Insights into Patient Outreach: Traditio...

FDA’s New Concept of Operations for Drug Inspections and Evaluations: What You Need to Do Today

FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

Appendix M of the NIH Guidelines: Reporting Requirements and Best Practices

10 Sure-Fire Tips for Developing a Document Management System Any Investigator Would Love

SOPs and Policies for the 21st Century: Why Less Is More

Editor's Picks

Stakeholders Urge Congress to Update Clinical Laboratory Diagnostics Legislation

Seniors Paying More for Generics Through Medicare Part D, Study Finds

NEXMED ANNOUNCES TERMINATION OF ALPROX-TD AGREEMENT WITH SCHERING AG AND PROVIDES OPERATIONAL UPDATE

Related Products

Environmental and Microbiological Monitoring at Drug Manufacturing Sites

FDA’s New Food Safety Regulations - Part One - Webinar CD/Transcript

FDA’s New Food Safety Regulations - Part Two - Webinar CD/Transcript